Summary
11.87
-0.88
(-6.90%)
06/05/2026
MiNK Therapeutics, Inc. (INKT)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| -6.90 | -4.12 | 2.86 | 8.40 | 3.22 | 62.83 | -90.11 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | C |
| Recommended Rating | Sell |
| DCF | Strong Sell |
| ROE | Strong Buy |
| ROA | Strong Sell |
| Debt/Equity | Strong Sell |
| P/E | Strong Sell |
| P/B | Strong Sell |
Earnings
| Trading Data | ||
| Close | 11.87 | |
| Open | 12.66 | |
| High | 12.89 | |
| Low | 11.49 | |
| Volume | 51,878 | |
| Change | -0.88 | |
| Change % | -6.90 | |
| Avg Volume (20 Days) | 46,661 | |
| Volume/Avg Volume (20 Days) Ratio | 1.11 | |
| 52 Week Range | 6.80 - 76.00 | |
| Price vs 52 Week High | -84.38% | |
| Price vs 52 Week Low | 74.56% | |
| Range | -6.24 | |
| Gap Up/Down | -0.74 | |
Profitibility | ||
| Market Capitalization (Mln) | 61 | |
| Revenue per share | 0.0000 | |
| Net Income per share | -2.5990 | |
| Dividend Yield | 0.0000 | |
| Dividend Share | 0.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | -4.5672 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
06/03 16:30 EST - globenewswire.com
MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced that its Annual Shareholders Meeting will begin at 9:30 a.m. ET....
MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced that its Annual Shareholders Meeting will begin at 9:30 a.m. ET....
05/28 09:04 EST - globenewswire.com
MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
NEW YORK and LVIV, Ukraine, May 28, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic iNKT cell therapies for cancer and immune disorders, today announced that the first patient has been dosed in its randomized...
MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
NEW YORK and LVIV, Ukraine, May 28, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic iNKT cell therapies for cancer and immune disorders, today announced that the first patient has been dosed in its randomized...
05/20 11:07 EST - globenewswire.com
MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company developing allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced new...
MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company developing allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced new...
05/15 16:50 EST - seekingalpha.com
MiNK Therapeutics, Inc. (INKT) Q1 2026 Earnings Call Transcript
MiNK Therapeutics, Inc. (INKT) Q1 2026 Earnings Call Transcript
MiNK Therapeutics, Inc. (INKT) Q1 2026 Earnings Call Transcript
MiNK Therapeutics, Inc. (INKT) Q1 2026 Earnings Call Transcript
05/15 10:12 EST - marketbeat.com
MiNK Therapeutics Q1 Earnings Call Highlights
MiNK Therapeutics NASDAQ: INKT said it is advancing its off-the-shelf invariant natural killer T cell therapy platform into a randomized clinical program for severe acute lung injury and acute respiratory distress syndrome, while also reporting first-quarter 2026 financial results that management...
MiNK Therapeutics Q1 Earnings Call Highlights
MiNK Therapeutics NASDAQ: INKT said it is advancing its off-the-shelf invariant natural killer T cell therapy platform into a randomized clinical program for severe acute lung injury and acute respiratory distress syndrome, while also reporting first-quarter 2026 financial results that management...
05/15 07:30 EST - globenewswire.com
MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation
Randomized Phase 2 trial initiated for agenT-797 in severe acute lung injury and respiratory distress, with preliminary data expected in the second half of 2026 AACR and ASGCT presentations showcase durable survival and context-dependent iNKT activity in cancer and inflammatory lung disease...
MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation
Randomized Phase 2 trial initiated for agenT-797 in severe acute lung injury and respiratory distress, with preliminary data expected in the second half of 2026 AACR and ASGCT presentations showcase durable survival and context-dependent iNKT activity in cancer and inflammatory lung disease...
05/14 07:30 EST - globenewswire.com
MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
NEW YORK and LVIV, Ukraine, May 14, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic iNKT cell therapies for cancer and immune disorders, and First Lviv Territorial Medical Union today announced the initiation of a randomized...
MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
NEW YORK and LVIV, Ukraine, May 14, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic iNKT cell therapies for cancer and immune disorders, and First Lviv Territorial Medical Union today announced the initiation of a randomized...
05/12 07:35 EST - globenewswire.com
MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026
iNKT therapy, agenT-797, delivers context-dependent immune reprogramming showing activation in cancer and anti-inflammatory benefit in ARDS - from the same manufacturing donor batch, without genetic engineering Findings underscore the intrinsic biology of iNKT cells and the manufacturing scale for...
MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026
iNKT therapy, agenT-797, delivers context-dependent immune reprogramming showing activation in cancer and anti-inflammatory benefit in ARDS - from the same manufacturing donor batch, without genetic engineering Findings underscore the intrinsic biology of iNKT cells and the manufacturing scale for...
05/08 16:30 EST - globenewswire.com
MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs
NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that it will report financial results for the...
MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs
NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that it will report financial results for the...
04/05 02:17 EST - defenseworld.net
MiNK Therapeutics, Inc. (NASDAQ:INKT) Given Average Recommendation of “Hold” by Brokerages
MiNK Therapeutics, Inc. (NASDAQ: INKT - Get Free Report) has received a consensus rating of "Hold" from the five research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating, one has assigned a buy...
MiNK Therapeutics, Inc. (NASDAQ:INKT) Given Average Recommendation of “Hold” by Brokerages
MiNK Therapeutics, Inc. (NASDAQ: INKT - Get Free Report) has received a consensus rating of "Hold" from the five research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating, one has assigned a buy...
04/03 07:30 EST - globenewswire.com
MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026
NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced that...
MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026
NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced that...
04/01 07:30 EST - globenewswire.com
MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference
NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced that...
MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference
NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced that...
03/31 11:02 EST - seekingalpha.com
MiNK Therapeutics, Inc. (INKT) Q4 2025 Earnings Call Transcript
MiNK Therapeutics, Inc. (INKT) Q4 2025 Earnings Call Transcript
MiNK Therapeutics, Inc. (INKT) Q4 2025 Earnings Call Transcript
MiNK Therapeutics, Inc. (INKT) Q4 2025 Earnings Call Transcript
03/31 07:30 EST - globenewswire.com
MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum
NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today reported...
MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum
NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today reported...
03/27 02:39 EST - defenseworld.net
MiNK Therapeutics, Inc. (NASDAQ:INKT) Sees Large Increase in Short Interest
MiNK Therapeutics, Inc. (NASDAQ: INKT - Get Free Report) was the target of a significant growth in short interest in March. As of March 13th, there was short interest totaling 149,702 shares, a growth of 303.4% from the February 26th total of 37,106 shares. Based on an average daily trading volume,...
MiNK Therapeutics, Inc. (NASDAQ:INKT) Sees Large Increase in Short Interest
MiNK Therapeutics, Inc. (NASDAQ: INKT - Get Free Report) was the target of a significant growth in short interest in March. As of March 13th, there was short interest totaling 149,702 shares, a growth of 303.4% from the February 26th total of 37,106 shares. Based on an average daily trading volume,...
03/17 07:30 EST - globenewswire.com
MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs
Recent milestones include strategic collaboration with C-Further to advance PRAME-targeted iNKT cell therapy for pediatric cancers, with meaningful downstream commercial revenue potential Recent milestones include strategic collaboration with C-Further to advance PRAME-targeted iNKT cell therapy...
MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs
Recent milestones include strategic collaboration with C-Further to advance PRAME-targeted iNKT cell therapy for pediatric cancers, with meaningful downstream commercial revenue potential Recent milestones include strategic collaboration with C-Further to advance PRAME-targeted iNKT cell therapy...
03/11 09:24 EST - benzinga.com
Why Is MiNK Therapeutics Stock Trading Lower On Wednesday?
MiNK Therapeutics Inc. (NASDAQ: INKT) shares are down during Wednesday's premarket session, possibly on profit-taking after the stock rallied roughly 30% on Tuesday.
Why Is MiNK Therapeutics Stock Trading Lower On Wednesday?
MiNK Therapeutics Inc. (NASDAQ: INKT) shares are down during Wednesday's premarket session, possibly on profit-taking after the stock rallied roughly 30% on Tuesday.
03/10 09:47 EST - benzinga.com
MiNK Therapeutics Pediatric Cancer Breakthrough Sparks Stock Rally
Under the collaboration, MiNK Therapeutics will receive approximately $1.1 million in non-dilutive funding to support the development of its PRAME-TCR-iNKT asset.
MiNK Therapeutics Pediatric Cancer Breakthrough Sparks Stock Rally
Under the collaboration, MiNK Therapeutics will receive approximately $1.1 million in non-dilutive funding to support the development of its PRAME-TCR-iNKT asset.
03/10 05:30 EST - globenewswire.com
MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT) a clinical-stage biopharmaceutical company advancing invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases, today announced a strategic collaboration with C-Further, an international...
MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT) a clinical-stage biopharmaceutical company advancing invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases, today announced a strategic collaboration with C-Further, an international...
Market News
×
Loading news…